An unusual presentation and a new treatment of eccrine syringofibroadenoma
DOI:
https://doi.org/10.66344/jpad.16.2.2006.859Keywords:
Eccrine syringofibroadenoma, bullous pemphigoid, etretinateAbstract
Eccrine syringofibroadenoma (ES) is a rare disease that clinically ranges from nodule on extremity to diffuse forms. A case of ES was assessed and compared with classification of ES. Our case had diffuse verrucous lesions since infancy, hypotrichosis, and loss of teeth. She had coincidental bullous pemphigoid. The patient was successfully treated with etretinate.
Â
References
Simpson EL, Styles HR, Cockerell CJ. Eccrine syringofibroadenomatosis associated with hidrotic ectodermal dysplasia. Br J Dermatol 1998; 138: 879-84.
Starink TM. Eccrine syringofrbroadenoma: multiple lesions representing a new cutaneous marker of the Shöpf syndrome, and solitary nonhereditary tumors. J Am Acad Dermatol 1997; 36: 569-76.
Mehregan AH, Marufi M, Medenica M. Eccrine syringo-fibroadenoma (Mascaro). J Am Acad Dermatol 1985; 13: 433-6.
Onnishi T, Suzuki T, Watanabe S. Eccrine syringofibroadenoma. Report of a case and immunohistochemical study of keration expression. Br J Dermatol 1995; 134: 449-54.
Utani A, Yabunami H, Kakuta T et al. Reactive eccrine syringofibroadenoma: An association with chronic foot ulcer in a patient with diabetes mellitus. J Am Acad Dermatol 1999; 41: 650-1.
Nomura K, Hashimoto I. Eccrine syringofibroadenomatosis in two patients with bullous pemphigoid. Dermatology 1997; 195: 395-8.
Downloads
Published
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
